AU2012238379C1 - Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents - Google Patents

Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents Download PDF

Info

Publication number
AU2012238379C1
AU2012238379C1 AU2012238379A AU2012238379A AU2012238379C1 AU 2012238379 C1 AU2012238379 C1 AU 2012238379C1 AU 2012238379 A AU2012238379 A AU 2012238379A AU 2012238379 A AU2012238379 A AU 2012238379A AU 2012238379 C1 AU2012238379 C1 AU 2012238379C1
Authority
AU
Australia
Prior art keywords
methyl
hydroxy
pyrazol
alkyl
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012238379A
Other languages
English (en)
Other versions
AU2012238379B2 (en
AU2012238379A1 (en
Inventor
Matthew F. Brown
Jinshan Michael Chen
Michael Melnick
Justin I. MONTGOMERY
Usa Reilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2012238379A1 publication Critical patent/AU2012238379A1/en
Publication of AU2012238379B2 publication Critical patent/AU2012238379B2/en
Priority to AU2015203287A priority Critical patent/AU2015203287A1/en
Application granted granted Critical
Publication of AU2012238379C1 publication Critical patent/AU2012238379C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2012238379A 2011-04-08 2012-03-27 Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents Ceased AU2012238379C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015203287A AU2015203287A1 (en) 2011-04-08 2015-06-16 Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473370P 2011-04-08 2011-04-08
US61/473,370 2011-04-08
PCT/IB2012/051456 WO2012137099A1 (en) 2011-04-08 2012-03-27 Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015203287A Division AU2015203287A1 (en) 2011-04-08 2015-06-16 Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Publications (3)

Publication Number Publication Date
AU2012238379A1 AU2012238379A1 (en) 2013-10-03
AU2012238379B2 AU2012238379B2 (en) 2015-03-19
AU2012238379C1 true AU2012238379C1 (en) 2015-08-06

Family

ID=45937499

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012238379A Ceased AU2012238379C1 (en) 2011-04-08 2012-03-27 Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Country Status (12)

Country Link
US (1) US8809333B2 (https=)
EP (1) EP2694481B1 (https=)
JP (1) JP2014514299A (https=)
KR (1) KR20130140164A (https=)
CN (1) CN103492368A (https=)
AU (1) AU2012238379C1 (https=)
CA (1) CA2830866A1 (https=)
IL (1) IL228798A (https=)
MX (1) MX2013011432A (https=)
SG (1) SG193458A1 (https=)
WO (1) WO2012137099A1 (https=)
ZA (1) ZA201306877B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032147A2 (en) 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
DK2512474T3 (en) 2009-12-16 2014-12-01 Pfizer N-linked hydroxamic acid derivatives which can be used as antibacterial agents
MA34963B1 (fr) 2011-03-07 2014-03-01 Pfizer Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
EP2948450A4 (en) * 2013-01-28 2016-11-09 Viamet Pharmaceuticals Inc METALLOENZYMINHIBITORVERBINDUNGEN
AR097617A1 (es) * 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AU2014368619B2 (en) * 2013-12-19 2018-11-22 Idorsia Pharmaceuticals Ltd Antibacterial 1H-indazole and 1H-indole derivatives
AR099612A1 (es) * 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
ES2687040T3 (es) 2014-05-16 2018-10-23 Idorsia Pharmaceuticals Ltd Derivados antibacterianos de quinazolin–4(3H)–ona
SG11201703992YA (en) * 2014-11-19 2017-06-29 Actelion Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
HRP20192009T1 (hr) 2014-12-16 2020-02-07 Novartis Ag Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105848A1 (es) * 2015-08-31 2017-11-15 Actelion Pharmaceuticals Ltd Derivados heterocíclicos antibacterianos
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
TW201741308A (zh) * 2016-05-17 2017-12-01 愛杜西亞製藥有限公司 6-(丁-1,3-二炔-1-基)苯并[d]噻唑衍生物
ES2643856B1 (es) * 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
SG11201810656WA (en) 2016-06-14 2018-12-28 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
AU2017337946B2 (en) * 2016-09-28 2020-05-07 Dong-A St Co., Ltd. Tetrahydropyridine derivatives and their use as antibacterial agents
RU2019133646A (ru) 2017-03-30 2021-04-30 Ф. Хоффманн-Ля Рош Аг Изохинолины в качестве ингибиторов hpk1
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
CN112601584A (zh) 2018-07-24 2021-04-02 豪夫迈·罗氏有限公司 异喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
DE202021105689U1 (de) 2021-10-19 2021-11-11 Punit Kumar Dwivedi Intelligentes System zur Verbesserung des Zustands der Batterien von Elektrofahrzeugen durch maschinelles Lernen und künstliche Intelligenz

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178042A1 (en) * 2008-09-19 2011-07-21 Pfizer Inc. Hydroxamic Acid Derivatives Useful as Antibacterial Agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59139388A (ja) * 1984-01-20 1984-08-10 Ajinomoto Co Inc トリアゾ−ル−４−カルボン酸誘導体
US4769461A (en) 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US5110831A (en) 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
GB2349884A (en) 1998-02-07 2000-11-15 British Biotech Pharm Antibacterial agents
GB9925470D0 (en) 1999-10-27 1999-12-29 Smithkline Beecham Plc Novel compounds
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
ES2180456B1 (es) 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
JP2004196678A (ja) * 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
CA2851462A1 (en) 2003-01-08 2004-07-29 University Of Washington Antibacterial agents
GB0302431D0 (en) 2003-01-30 2003-03-05 Glaxo Group Ltd Novel compounds
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
WO2006118155A1 (ja) 2005-04-27 2006-11-09 Ishihara Sangyo Kaisha, Ltd. ビフェニル誘導体又はその塩、並びにそれらを有効成分として含有する農園芸用殺菌剤
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
WO2007069020A2 (en) * 2005-12-15 2007-06-21 Vicuron Pharmaceuticals Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2008045671A1 (en) 2006-10-06 2008-04-17 Janssen Pharmaceutica, N.V. Matrix metalloprotease inhibitors
US7879911B2 (en) 2007-02-01 2011-02-01 Johnson Alan T Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
WO2008105515A1 (ja) 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
EP2235750A1 (en) * 2007-11-27 2010-10-06 Nxp B.V. Contact structure for an electronic circuit substrate and electronic circuit comprising said contact structure
EP2315746A1 (en) 2008-08-04 2011-05-04 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011045703A2 (en) * 2009-10-13 2011-04-21 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
DK2512474T3 (en) 2009-12-16 2014-12-01 Pfizer N-linked hydroxamic acid derivatives which can be used as antibacterial agents
MA34963B1 (fr) * 2011-03-07 2014-03-01 Pfizer Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178042A1 (en) * 2008-09-19 2011-07-21 Pfizer Inc. Hydroxamic Acid Derivatives Useful as Antibacterial Agents

Also Published As

Publication number Publication date
KR20130140164A (ko) 2013-12-23
IL228798A0 (en) 2013-12-31
CN103492368A (zh) 2014-01-01
AU2012238379B2 (en) 2015-03-19
US20140038975A1 (en) 2014-02-06
WO2012137099A1 (en) 2012-10-11
US8809333B2 (en) 2014-08-19
AU2012238379A1 (en) 2013-10-03
ZA201306877B (en) 2014-11-26
EP2694481A1 (en) 2014-02-12
JP2014514299A (ja) 2014-06-19
MX2013011432A (es) 2013-12-09
IL228798A (en) 2015-05-31
CA2830866A1 (en) 2012-10-11
SG193458A1 (en) 2013-10-30
EP2694481B1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
AU2012238379C1 (en) Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
AU2012238374B2 (en) Isoxazole derivatives useful as antibacterial agents
CA2782453C (en) N-linked hydroxamic acid derivatives useful as antibacterial agents
US6403620B1 (en) Inhibitors of factor Xa with a neutral P1 specificity group
CA2747784C (en) Imidazole compounds for use as enzyme inhibitors
TW572757B (en) Novel isoxazolinone antibacterial agents
TWI802591B (zh) 具有環狀構造的化合物
EA021359B1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
EA010132B1 (ru) Производные триазола в качестве антагонистов вазопрессина
SI20818A (sl) N-heterociklični derivati kot nos inhibitorji
EA003056B1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
AU2009240856A1 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
IL235372A (en) Triazolone compounds as mpges inhibitors–
TW200524896A (en) Novel indazole derivative
JP2002507968A (ja) 中性のＰ１特異性基を有するＸａ因子阻害剤
WO2019136147A1 (en) Toll-like receptor signaling inhibitors
CN101511815A (zh) 新型吡啶类似物
US20240317767A1 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
AU2007309567A1 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
KR19990063989A (ko) 염증 치료용의 1,3,5-삼치환된 피라졸 화합물
JP7550777B2 (ja) ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
JP2008513427A (ja) 炎症の治療に有用なピラゾール化合物
AU2015203287A1 (en) Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
SG178043A1 (en) Substituted benzamide derivatives as glucokinase (gk) activators
HK1190155A (en) Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JUL 2015

MK14 Patent ceased section 143(a) (annual fees not paid) or expired